NuPeak Therapeutics

NuPeak Therapeutics is a private biotechnology company based in the St. Louis, Missouri area focused on developing first-in-class small-molecule kinase inhibitors for respiratory disease. Its lead program targets MAPK13 to reduce airway inflammation and mucus production in diseases such as asthma, chronic obstructive pulmonary disease, and post-viral respiratory conditions including COVID-19. The company works in concert with a long-running Washington University drug discovery program founded by Michael J. Holtzman, with NuPeak oriented toward IND-enabling development, toxicology, CMC, and early clinical preparation. Publicly available materials indicate the company is advancing inhaled and intravenous delivery strategies and positioning its lead asset for IND filing and Phase 1 readiness.